[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345268-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345268-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tyro3-axl-mertk-and-their-ligands-in-brain-metastases-from-colorectal-cancers","TYRO3, AXL, MERTK and Their Ligands in Brain Metastases From Colorectal Cancers","","Introduction: TYRO3, AXL, and MERTK (TAM receptor tyrosine kinases) represent potential therapeutic targets in metastatic colorectal cancer, with pre-clinical and clinical evidence needed to clarify their roles in the CNS and brain metastases from colorectal cancer (BM-CRC). Methods: TAM receptor expression was assessed in established BM-CRC stem cell lines, a local BM-CRC cohort, and metastatic CRC data from TCGA. Results: TYRO3 and AXL were broadly expressed in tumor sites, with GAS6 showing prognostic value. Conclusion: the GAS6 ligand and AXL/GAS6 ratio may help monitor prognosis in metastatic CRC, including BM-CRC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tyro3-axl-mertk-and-their-ligands-in-brain-metastases-from-colorectal-cancers/345268/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tyro3-axl-mertk-and-their-ligands-in-brain-metastases-from-colorectal-cancers/345268.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which TAM receptors and ligands were investigated in this study?","Question",{"text":63,"@type":64},"The study examined TYRO3, AXL, and MERTK (TAM receptor tyrosine kinases) and their ligands Protein S (PROS1) and GAS6, focusing on their presence in BM-CRC contexts.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was TAM receptor expression analyzed across samples?",{"text":68,"@type":64},"TAM receptor expression was evaluated in established BM-CRC stem cell lines (RNA and protein), in a local patient cohort using protein, and in TCGA metastatic CRC using RNA.",{"name":70,"@type":61,"acceptedAnswer":71},"What prognostic association was found in metastatic CRC data?",{"text":72,"@type":64},"None of the TAM receptors or PROS1 were prognostic in the TCGA metastatic CRC cohort, but GAS6 was prognostic in both univariate and multivariate analyses, and Low AXL/High GAS6 correlated with poorer prognosis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345268,1790940098,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nTYRO3, AXL, MERTK and Their Ligands in Brain Metastases From Colorectal Cancers  \nAnaïs Noblanc1,2 | Fatima Dkhissi1 | Pierre-Olivier Guichet1,2 | Lucie Lebeau3 | Serge Milin3 | Sheik Emambux1,4 | Pauline Roussille5 | Camille Evrard1,4  | Lucie Karayan-Tapon1,2 | David Tougeron1,6 | Omar Benzakour1 | Violaine Randrian1,6   \n1PRODICET, UR24144, Université de Poitiers, Poitiers, France | 2Department of Biological Cancerology, CHU de Poitiers, Poitiers, France | 3Department of Pathology, CHU de Poitiers, Poitiers, France | 4Department of Oncology, CHU de Poitiers, Poitiers, France | 5Department of Radiotherapy, CHU de Poitiers, Poitiers, France | 6Department of Hepatology and Gastroenterology, CHU de Poitiers, Poitiers, France  \nCorrespondence: Violaine Randrian ([violaine.randrian@chu-poitiers.fr](violaine.randrian@chu-poitiers.fr))  \nReceived: 18 March 2025 | Revised: 30 March 2026 | Accepted: 15 April 2026  \nKeywords: AXL | brain metastasis | colorectal cancer | GAS6  \nABSTRACT  \nIntroduction: TYRO3, AXL, and MERTK (TAM receptor tyrosine kinases) represent potential therapeutic targets in metastatic colorectal cancer. Pre-clinical and clinical data are needed to explore further how TAM receptors interact with the central nervous system, which could impact brain metastases from colorectal cancer (BM-CRC) .  \nMethods: We analyzed TAM receptor expression in established brain metastasis stem cell lines from patients with CRC (BMSC-CRC) (RNA and protein), a local cohort of BM-CRC patients (protein), and a cohort of metastatic CRC from The Cancer Genome Atlas (TCGA) (RNA) .  \nResults: When orthotopically injected into mice, BM-SC-CRC derived from two patients expressed TYRO3 and Protein S (PROS1) but poorly AXL and GAS6 . When we analyzed both patients' primary tumors and metastatic sites, TYRO3 and AXL proteins were expressed in all tumor sites, but hardly MERTK. AXL was located primarily in endothelial cells, and TYRO3 in tumor cells. We examined the protein expression of TAM receptors in a cohort of BM-CRC patients, considering tissue from the primary tumor (N = 85), the matched brain metastases (N = 40), and another metastatic site (N = 29). AXL was expressed through primary tumors to brain metastases, as 72.7% of samples in BM (versus 44% with TYRO3 and 53% with MERTK) had a stable (45.5%) or increased (27.2%) protein expression compared to their paired primary tumor. None of the TAM receptors or PROS1 were found prognostic in a TCGA metastatic CRC cohort (n = 80), but GAS6 was, in univariate (HR = 2.141 [95% CI 1.018–4.506], p = 0.045) and multivariate analysis (HR = 2.382 [95% CI 1.124–5.048], p = 0.024) . In exploratory analysis, patients with Low AXL/High GAS6 had a poorer prognosis (p = 0.046) .  \nDiscussion and Conclusion: The TAM receptors' ligand GAS6 and the AXL/GAS6 ratio could help to monitor patients' prognosis in metastatic CRC settings including BM-CRC. Further research is needed to validate the TAM receptors' impact on prognosis in BM-CRC.  \n\n| Omar Benzakour and Violaine Randrian contributed equally to this work and are co-last authors. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.\u003Cbr>© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. |\n\nCancer Medicine, 2026; 15:e71869 1 of 15  \n[https://doi.org/10.1002/cam4.71869](https://doi.org/10.1002/cam4.71869)  \n1 | Introduction  \nUnlike brain metastases (BM) from lung cancer or melanoma, BM from colorectal cancer (BM-CRC) are mainly metachronous and of poorer prognosis [1]. This difference in disease history indicates a distinct physiology. BM-CRCs are usually associated with the terminal evolution of CRC, since most BM occur more than 2 years after dia","cbCaiohnc7cvEO3Z","https://ap.wps.com/l/cbCaiohnc7cvEO3Z","pdf",8593178,15,"English","# Introduction\n# Methods\n# Results\n# Discussion and Conclusion","[{\"question\":\"Which TAM receptors and ligands were investigated in this study?\",\"answer\":\"The study examined TYRO3, AXL, and MERTK (TAM receptor tyrosine kinases) and their ligands Protein S (PROS1) and GAS6, focusing on their presence in BM-CRC contexts.\"},{\"question\":\"How was TAM receptor expression analyzed across samples?\",\"answer\":\"TAM receptor expression was evaluated in established BM-CRC stem cell lines (RNA and protein), in a local patient cohort using protein, and in TCGA metastatic CRC using RNA.\"},{\"question\":\"What prognostic association was found in metastatic CRC data?\",\"answer\":\"None of the TAM receptors or PROS1 were prognostic in the TCGA metastatic CRC cohort, but GAS6 was prognostic in both univariate and multivariate analyses, and Low AXL/High GAS6 correlated with poorer prognosis.\"}]","TYRO3, AXL, MERTK and Their Ligands in Brain Metastases From Colorectal Cancers | PDF",1790057026,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85ca3528679b896cddb46e5e0c6dd53d.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b81bee7d3c0f8aefc53c28edb0fac5d5.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62e8fad2952876bbbaf64a6e2a61dafe.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ec3cdd449c2a15257f1c4611158a12f.webp",980,1287]